Zacks Research Downgrades Bruker (NASDAQ:BRKR) to Hold

Bruker (NASDAQ:BRKR) was downgraded by investment analysts at Zacks Research from a “strong-buy” rating to a “hold” rating in a note issued to investors on Wednesday, Zacks reports.

A number of other equities research analysts have also recently issued reports on the stock. UBS Group set a $60.00 target price on shares of Bruker in a research report on Wednesday, June 24th. Barclays lifted their price objective on shares of Bruker from $53.00 to $60.00 and gave the stock an “overweight” rating in a research note on Wednesday, June 24th. Guggenheim boosted their price objective on shares of Bruker from $50.00 to $70.00 and gave the company a “buy” rating in a report on Monday, June 29th. Weiss Ratings reaffirmed a “sell (d+)” rating on shares of Bruker in a report on Monday. Finally, JPMorgan Chase & Co. lifted their price target on shares of Bruker from $55.00 to $65.00 and gave the company an “overweight” rating in a research report on Monday, June 8th. One analyst has rated the stock with a Strong Buy rating, six have given a Buy rating, five have given a Hold rating and two have assigned a Sell rating to the stock. Based on data from MarketBeat.com, the stock presently has an average rating of “Hold” and a consensus target price of $56.64.

Bruker Stock Performance

NASDAQ:BRKR opened at $59.41 on Wednesday. The stock has a 50 day simple moving average of $58.81 and a 200 day simple moving average of $48.57. The stock has a market cap of $9.05 billion, a P/E ratio of -84.87, a PEG ratio of 1.81 and a beta of 1.26. Bruker has a 1-year low of $28.95 and a 1-year high of $65.30. The company has a current ratio of 1.85, a quick ratio of 0.92 and a debt-to-equity ratio of 0.76.

Bruker (NASDAQ:BRKR) last issued its quarterly earnings data on Tuesday, August 4th. The medical research company reported $0.49 EPS for the quarter, beating analysts’ consensus estimates of $0.38 by $0.11. The firm had revenue of $838.50 million for the quarter, compared to analyst estimates of $853.57 million. Bruker had a positive return on equity of 12.47% and a negative net margin of 2.35%.The company’s revenue for the quarter was up 5.2% on a year-over-year basis. During the same period in the prior year, the firm posted $0.32 EPS. Bruker has set its FY 2026 guidance at 2.100-2.150 EPS. Research analysts anticipate that Bruker will post 2.12 earnings per share for the current year.

Institutional Investors Weigh In On Bruker

A number of large investors have recently bought and sold shares of the company. Orbis Allan Gray Ltd raised its position in shares of Bruker by 5.4% in the 4th quarter. Orbis Allan Gray Ltd now owns 14,906,730 shares of the medical research company’s stock valued at $702,256,000 after buying an additional 761,258 shares in the last quarter. Pallas Capital Advisors LLC acquired a new stake in shares of Bruker during the 2nd quarter worth approximately $570,746,000. California State Teachers Retirement System increased its stake in Bruker by 5,982.2% in the second quarter. California State Teachers Retirement System now owns 7,455,459 shares of the medical research company’s stock valued at $448,670,000 after acquiring an additional 7,332,880 shares during the last quarter. State Street Corp increased its stake in Bruker by 2.5% in the fourth quarter. State Street Corp now owns 3,831,814 shares of the medical research company’s stock valued at $180,700,000 after acquiring an additional 91,706 shares during the last quarter. Finally, AQR Capital Management LLC raised its position in Bruker by 125.3% during the second quarter. AQR Capital Management LLC now owns 3,326,820 shares of the medical research company’s stock valued at $137,065,000 after purchasing an additional 1,850,215 shares in the last quarter. 79.52% of the stock is currently owned by institutional investors and hedge funds.

Bruker Company Profile

Bruker Corporation, founded in 1960 by physicist Günther Laukien and headquartered in Billerica, Massachusetts, is a leading developer and manufacturer of high-performance scientific instruments and analytical solutions. The company designs systems that enable molecular and materials research across academic, governmental, and industrial laboratories.

Bruker’s product portfolio encompasses nuclear magnetic resonance (NMR) spectrometers for molecular structure and dynamics studies, mass spectrometry platforms for proteomics and metabolomics, X-ray diffraction and scattering instruments for crystallography and materials characterization, atomic force and scanning probe microscopes for nanoscale surface analysis, as well as preclinical imaging systems such as micro-CT and MRI scanners.

In addition to hardware, Bruker provides software suites, applications support, training services, and long-term maintenance agreements to ensure optimal instrument performance.